Oncolys BioPharma News

Oncolys BioPharma: Announcements of individual stocks regarding the mass exercise of the 20th subscription rights (including the exercise price adjustment clause and exercise suspension clause) issued through third-party allotment.

Jul 25 03:00 ET

Oncolys BioPharma: Announcements of individual stocks: Final analysis results for the C-9 ALS Phase 2a trial of OBP-601 (censavudine, TPN-101).

Jul 24 19:00 ET

Oncolys BioPharma: Announcements of individual stocks regarding patent evaluation in OBP-801 ophthalmology field.

Jul 22 02:00 ET

Oncolys BioPharma: Announcements of individual stocks regarding responses to inquiries.

Jul 8 02:00 ET

Oncolys BioPharma: Mass Ownership Report

Jul 7 22:16 ET

Oncolys BioPharma: Announcement of the establishment of a new organization.

Jul 3 02:00 ET

Oncolys BioPharma: Announcements of the issuance of the 20th subscription rights (with exercise price adjustment clause and exercise suspension clause) through third-party allocation have been completed for payment.

Jul 1 02:00 ET

Oncolys BioPharma: Announcements of individual stocks regarding the issuance of the 20th subscription rights by third-party allocation (with modification clause for exercise price and suspension clause for exercise) and the conclusion of the purchase agreement (commitment issue) of subscription rights.

Jun 14 03:00 ET

Oncolys BioPharma: Supplementary explanatory materials regarding the issuance of the 20th subscription rights through third-party allocation.

Jun 14 03:00 ET

Oncolys BioPharma: Securities registration statement (referencing method).

Jun 14 02:00 ET

Oncolys BioPharma: Patients with esophageal gastric adenocarcinoma refractory to immunotherapy who were first enrolled in the OBP-301 phase 2 clinical trial of pembrolizumab initiated by the investigator responsible physician

Jun 3 02:00 ET

Oncolys BioPharma: Notice regarding the commencement of administration of the US Phase 2 clinical trial for second-line treatment of treatment-resistant gastric cancer containing anti-PD-1/PD-L1 antibodies to telomerysin

Jun 3 02:00 ET

Oncolys BioPharma: Notice regarding responses to inquiries

May 31 02:00 ET

Oncolys BioPharma: Notice regarding fast track designation of OBP-601 (censavudine, TPN-101) for progressive supranuclear palsy (PSP)

May 21 19:00 ET

Oncolys BioPharma: Confirmation letter

May 10 02:08 ET

Oncolys BioPharma: Quarterly Report - 21st Quarter (2024/01/01 to 2024/03/31)

May 10 02:07 ET

Oncolys BioPharma: Notice Concerning the Recording of Non-Operating Income and Non-Operating Expenses

May 10 02:00 ET

Oncolys BioPharma: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)

May 10 02:00 ET

Oncolys BioPharma: Unconsolidated financial results for the three months ended 2024/3/31 [Japanese GAAP]

May 10 02:00 ET

Oncolis Biopharma: Notice regarding responses to inquiries

Apr 9 02:00 ET